Desley van Zoggel

Induction chemotherapy in locally recurrent rectal cancer 25 CHAPTER 2 Results During the selected time frame, ICT was incorporated into the multimodality management of 58patients, and71 patients receivedconcurrent CRRTalone. Patient and neoadjuvant treatment characteristics are shown inTable 1. Apart fromsex differences, there were no significantly different characteristics between the two groups. Table 1. Patient and neoadjuvant treatment characteristics for all resected patients ICT + CRRT CRRT alone P-value N = 58 N = 71 Age (years)* 64 (33-76) 65 (30-84 0.297 Sex ratio (M:F) 46:12 40:31 0.006 Stage of primary tumour† 0 1 (2) 1 (1) 0.080 I 3 (5) 13 (19) II 13 (22) 19 (27) III 35 (60) 35 (50) IV 6 (10) 2 (3) (Neo)adjuvant treatment for primary tumour None/chemotherapy alone‡ 4 (7) 5 (7) 0.697 Radiotherapy (5x5 Gy) 22 (38) 32 (45) Chemoradiotherapy 32 (55) 34 (48) History of metastases§ No 40 (69) 55(78) 0.276 Yes 18 (31) 16 (23) Type of primary surgery Hartmann procedure 3 (5) 2 (3) 0.073 Rectosigmoid resection 2 (3) 0 (0) Low anterior resection 27 (47) 38 (54) Abdominoperineal/ abdominosacral resection 23 (40) 22 (31) Total exenteration 3 (5) 2 (3) Other/unknown 0 (0) 7 (10) Local recurrence First 51 (88) 65 (92) 0.570 Second 6 (10) 4 (6) Third 1 (2) 2 (3) Values in parentheses are percentages unless indicated otherwise; *values are median (range). †Information on the primary tumour could not be retrieved for one patient in the chemoradiation therapy (CRRT) group. ‡These patients did receive full-course radiotherapy for a previous recurrence. § Metachronous or synchronous resectable metastases. ‡χ2 test, except §t test ICT induction chemotherapy.

RkJQdWJsaXNoZXIy MTk4NDMw